HC Wainwright keeps Buy rating on Immunocore with $100 price target
HC Wainwright reiterated its Buy rating on Immunocore shares with a $100 target, implying 222.8% upside from the October 23 close, per TradingView citing Benzinga.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Analysts at HC Wainwright & Co. reiterated their Buy rating on Immunocore Holdings and kept the price target at $100. According to TradingView, citing Benzinga, the target implies an upside of 222.8% from the October 23 close of $30.98.
The analyst note points to a pipeline of clinical-stage programs, including brenetafusp and IMC-P115C, with data expected by late 2026 that could strengthen the company's position. It also highlights the commercial performance of KIMMTRAK in unresectable or metastatic uveal melanoma.
why it matters
Rating updates of this kind usually affect only the company's own shares and rarely move the wider market. For Immunocore investors, the timing of data readouts for brenetafusp and IMC-P115C remains the key factor the analysts flag for the stock.
tags
instruments
sources
- HC Wainwright & Co. reiterates Buy rating on Immunocore Holdings, $100 price target — TradingView, 26 October 2026 at 17:09 UTC
- Immunocore Holdings Price Target Maintained With a $100.00/Share by HC Wainwright & Co. — Dow Jones Newswires, 26 October 2026 at 17:19 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗